Featured Research

from universities, journals, and other organizations

Battle of the bulge occurs in the liver

Date:
June 23, 2014
Source:
Monash University
Summary:
An international team of scientists has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease. Type 2 diabetes and non-alcoholic fatty liver disease are key complications of obesity as 80 per cent of patients with type 2 diabetes are obese, and 75 per cent of patients who are obese or have type 2 diabetes also have fatty liver disease.

An international team of scientists led by Monash University researchers has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease.

Type 2 diabetes and non-alcoholic fatty liver disease are key complications of obesity as 80 per cent of patients with type 2 diabetes are obese, and 75 per cent of patients who are obese or have type 2 diabetes also have fatty liver disease.

The team, led by Professor Tony Tiganis from the Department of Biochemistry and Molecular Biology at Monash, has found that free radical molecules called Reactive Oxygen Species (ROS) wage a battle with enzymes called protein tyrosine phosphatases, initiating a cascade of events with devastating consequences.

The findings, published in the journal Cell Metabolism, explain how selective insulin resistance -- a pathological feature of type 2 diabetes -- occurs in the liver. The study identifies the molecular culprits involved, and reveals how they contribute to disease progression.

"We have shown for the very first time that these free radicals inactivate protein tyrosine phosphatases in the liver to activate rogue pathways that promote fatty liver disease and exacerbate the development of obesity and type 2 diabetes," Professor Tiganis said.

Professor Tiganis' team found in lab studies that obesity promoted ROS generation that inactivated a phosphatase called PTPN2. This inactivation in turn exacerbated obesity and fatty liver disease progression.

While there is more work to be done to understand the causes of fatty liver disease, Professor Tiganis has plans to test two potential therapeutic approaches. One involves inactivating a protein in the liver, and the other will use a selective anti-oxidant to 'mop up' excess free radicals that would otherwise inactivate PTPN2.

While free radicals play important roles in disease, Professor Tiganis advises against taking anti-oxidants indiscriminately.

"Although we need to undertake further studies in humans, preclinical studies indicate that ROS also play important roles in biology," he said.


Story Source:

The above story is based on materials provided by Monash University. Note: Materials may be edited for content and length.


Journal Reference:

  1. EstebanN. Gurzov, Melanie Tran, ManuelA. Fernandez-Rojo, TroyL. Merry, Xinmei Zhang, Yang Xu, Atsushi Fukushima, MichaelJ. Waters, MatthewJ. Watt, Sofianos Andrikopoulos, BenjaminG. Neel, Tony Tiganis. Hepatic Oxidative Stress Promotes Insulin-STAT-5 Signaling and Obesity by Inactivating Protein Tyrosine Phosphatase N2. Cell Metabolism, 2014; DOI: 10.1016/j.cmet.2014.05.011

Cite This Page:

Monash University. "Battle of the bulge occurs in the liver." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623095738.htm>.
Monash University. (2014, June 23). Battle of the bulge occurs in the liver. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/06/140623095738.htm
Monash University. "Battle of the bulge occurs in the liver." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623095738.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins